Development of Mucosal Vaccine Delivery: an Overview on the Mucosal Vaccines and Their Adjuvants

Overview

Journal Clin Exp Vaccine Res

Date 2022 Dec 1

PMID 36451668

Authors

Rahmi Anggraeni

Ika Dewi Ana

Hevi Wihadmadyatami

Affiliations

Soon will be listed here.

Abstract

Currently, mucosal infectious diseases are still a very high global health burden, but there are few effective vaccines to prevent mucosal-borne diseases. The development of mucosal vaccines requires the selection of appropriate antigens, delivery system strategies, and adjuvants to increase vaccine efficacy but limited studies have been conducted. The aim of this review is to describe the mucosal immune system, as well as the potential for the development of vaccines and mucosal adjuvants, and their challenges. The study was conducted by applying inclusion criteria for the articles, and a review was conducted by two readers with the agreement. It was known that mucosal vaccination is a potential route to be applied in future preventive efforts through vaccination. However, limited studies have been conducted so far and limited mucosal vaccination has been approved. New technological approaches such as material development involving nano- and micro-patterning are important to intensively open and investigate the potential area of development to provide better vaccination methods.

Citing Articles

Pivotal role of virulence genes in pathogenicity and vaccine development.

Elbehiry A, Marzouk E, Abalkhail A, Sindi W, Alzahrani Y, Alhifani S Front Med (Lausanne). 2025; 11():1523991.

PMID: 39850097 PMC: 11756510. DOI: 10.3389/fmed.2024.1523991.

Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications.

Zhou M, Xiao H, Yang X, Cheng T, Yuan L, Xia N MedComm (2020). 2025; 6(2):e70056.

PMID: 39830020 PMC: 11739453. DOI: 10.1002/mco2.70056.

Applications of Chitosan in Prevention and Treatment Strategies of Infectious Diseases.

Sinani G, Sessevmez M, Senel S Pharmaceutics. 2024; 16(9).

PMID: 39339237 PMC: 11434819. DOI: 10.3390/pharmaceutics16091201.

In vitro/In vivo Evaluations of Hydroxyapatite Nanoparticles with Different Geometry.

Sun W, Zhong J, Gao B, Feng J, Ye Z, Lin Y Int J Nanomedicine. 2024; 19:8661-8679.

PMID: 39193530 PMC: 11348988. DOI: 10.2147/IJN.S469687.

Intranasal Vaccination with Recombinant TLR2-Active Outer Membrane Vesicles Containing Sequential M2e Epitopes Protects against Lethal Influenza a Challenge.

Kannan N, Choi A, Rivera De Jesus M, Wei P, Sahler J, Curley S Vaccines (Basel). 2024; 12(7).

PMID: 39066362 PMC: 11281606. DOI: 10.3390/vaccines12070724.

References

Neutra M, Kozlowski P . Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2):148-58. DOI: 10.1038/nri1777. View

Rhee J, Lee S, Kim S . Mucosal vaccine adjuvants update. Clin Exp Vaccine Res. 2013; 1(1):50-63. PMC: 3623511. DOI: 10.7774/cevr.2012.1.1.50. View

Kraan H, Vrieling H, Czerkinsky C, Jiskoot W, Kersten G, Amorij J . Buccal and sublingual vaccine delivery. J Control Release. 2014; 190:580-92. PMC: 7114675. DOI: 10.1016/j.jconrel.2014.05.060. View

Lavelle E, Ward R . Mucosal vaccines - fortifying the frontiers. Nat Rev Immunol. 2021; 22(4):236-250. PMC: 8312369. DOI: 10.1038/s41577-021-00583-2. View

Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, Nomura T . Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J Virol. 2010; 84(24):12703-12. PMC: 3004317. DOI: 10.1128/JVI.01182-10. View

Ainai A, van Riet E, Ito R, Ikeda K, Senchi K, Suzuki T . Human immune responses elicited by an intranasal inactivated H5 influenza vaccine. Microbiol Immunol. 2020; 64(4):313-325. PMC: 7216874. DOI: 10.1111/1348-0421.12775. View

Raghavan S, Ostberg A, Flach C, Ekman A, Blomquist M, Czerkinsky C . Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infect Immun. 2010; 78(10):4251-60. PMC: 2950356. DOI: 10.1128/IAI.00536-10. View

Ogra P, Faden H, Welliver R . Vaccination strategies for mucosal immune responses. Clin Microbiol Rev. 2001; 14(2):430-45. PMC: 88982. DOI: 10.1128/CMR.14.2.430-445.2001. View

Aoshi T . Modes of Action for Mucosal Vaccine Adjuvants. Viral Immunol. 2017; 30(6):463-470. PMC: 5512297. DOI: 10.1089/vim.2017.0026. View

10.

Kozlowski P, Aldovini A . Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission. Curr Immunol Rev. 2019; 15(1):102-122. PMC: 6709706. DOI: 10.2174/1573395514666180605092054. View

11.

Alving C, Peachman K, Rao M, Reed S . Adjuvants for human vaccines. Curr Opin Immunol. 2012; 24(3):310-5. PMC: 3383374. DOI: 10.1016/j.coi.2012.03.008. View

12.

Kabelitz D . Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol. 2006; 19(1):39-45. DOI: 10.1016/j.coi.2006.11.007. View

13.

Hovav A . Dendritic cells of the oral mucosa. Mucosal Immunol. 2013; 7(1):27-37. DOI: 10.1038/mi.2013.42. View

14.

Savelkoul H, Ferro V, Strioga M, Schijns V . Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines. Vaccines (Basel). 2015; 3(1):148-71. PMC: 4494243. DOI: 10.3390/vaccines3010148. View

15.

Lamichhane A, Azegamia T, Kiyonoa H . The mucosal immune system for vaccine development. Vaccine. 2014; 32(49):6711-23. DOI: 10.1016/j.vaccine.2014.08.089. View

16.

Gordon S, Kines R, Kutsyna G, Ma Z, Hryniewicz A, Roberts J . Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol. 2011; 188(2):714-23. PMC: 3253208. DOI: 10.4049/jimmunol.1101404. View

17.

Toussi D, Massari P . Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands. Vaccines (Basel). 2015; 2(2):323-53. PMC: 4494261. DOI: 10.3390/vaccines2020323. View

18.

Cesta M . Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol. 2006; 34(5):599-608. DOI: 10.1080/01926230600865531. View

19.

Chen K, Cerutti A . Vaccination strategies to promote mucosal antibody responses. Immunity. 2010; 33(4):479-91. PMC: 3045856. DOI: 10.1016/j.immuni.2010.09.013. View

20.

Bals R . Epithelial antimicrobial peptides in host defense against infection. Respir Res. 2001; 1(3):141-50. PMC: 59560. DOI: 10.1186/rr25. View